Thursday, September 28, 2023
BioCity Biopharma and AstraZeneca have entered into a collaborative agreement aimed at conducting a Phase Ib/II clinical study.
The collaboration between BioCity and AstraZeneca aims to assess the potential of combining BC3402 with durvalumab (IMFINZI) to enhance the clinical outcomes for individuals diagnosed with hepatocellular carcinoma (HCC).
The purpose of this study is to assess the safety and effectiveness of BioCity's BC3402, a monoclonal antibody designed to target TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), in combination with AstraZeneca's anti-PD-L1 monoclonal antibody IMFINZI, also known as durvalumab.
The focus of this joint research effort is to explore the potential treatment benefits of this combination therapy for patients with advanced hepatocellular carcinoma (HCC) in China.
BC3402 is a highly anti-TIM-3 monoclonal antibody (mAb) that outshines its counterparts in terms of binding affinity, making it a potential best-in-class candidate. This antibody possesses the unique capability to bind to multiple epitopes on TIM-3, a critical immune checkpoint protein. Moreover, BC3402 has demonstrated its effectiveness in blocking the interactions of TIM-3 with important molecules such as CEACAM1, PtdSer, and Gal-9.
Furthermore, BC3402 has showcased remarkable synergistic effects when combined with monoclonal antibodies targeting PD-1 and CTLA-4. These are pivotal targets in the clinical treatment of liver cancer. BC3402 has the potential to enhance the efficacy of immune checkpoint inhibitors, holding promise for more effective liver cancer therapies.
